Welcome to our dedicated page for LIFECORE BIOMEDICAL DE SEC filings (Ticker: LFCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LIFECORE BIOMEDICAL DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LIFECORE BIOMEDICAL DE's regulatory disclosures and financial reporting.
Lifecore Biomedical director Matthew E. Korenberg received a grant of 25,907 shares of common stock in the form of restricted stock units, with no cash paid per share. This award is compensation, not an open-market purchase, and increases his direct holdings to 69,967 shares.
The restricted stock units convert into common stock on a 1-for-1 basis and vest on the earlier of June 4, 2027 or the date of the Lifecore Biomedical annual stockholders meeting first held in calendar year 2027, provided that meeting occurs at least 50 weeks after June 4, 2026.
Director Humberto Calheiros Antunes of Lifecore Biomedical, Inc. reported receiving an award of 25,907 shares of common stock in the form of restricted stock units. The award has no cash exercise price and increases his direct holdings to 72,967 shares after the transaction.
The restricted stock units convert into common stock on a 1-for-1 basis and will vest on the earlier of June 4, 2027 or the date of Lifecore’s 2027 annual stockholders’ meeting, provided that meeting occurs at least 50 weeks after June 4, 2026.
Lifecore Biomedical director Paul Harold Johnson received an equity award of 25,907 restricted stock units that convert into common stock on a 1-for-1 basis. The award is recorded at a price of $0.00 per share as a grant/award acquisition and is held directly.
The units vest on the earlier of June 4, 2027 or the date of the company’s annual meeting of stockholders first held in calendar year 2027, provided that meeting occurs at least 50 weeks after June 4, 2026. Following this grant, Johnson holds 69,967 shares of common stock.
Lifecore Biomedical director Katrina Houde received an equity grant in the form of restricted stock units. She was awarded 25,907 shares of Common Stock on June 4, 2026 as a grant or award, at a stated price of $0.00 per share, indicating compensation rather than an open-market purchase.
After this grant, Houde directly holds 135,319 shares of Lifecore Biomedical common stock. According to the footnotes, the restricted stock units convert into common stock on a 1-for-1 basis and vest on the earlier of June 4, 2027 or the date of the company’s 2027 annual stockholder meeting, provided that meeting occurs at least 50 weeks after the grant date.
Lifecore Biomedical, Inc. reported results from its 2026 annual meeting of stockholders. Investors approved the 2026 Stock Incentive Plan, which will authorize 2,500,000 shares of common stock for equity awards, plus any shares returning from forfeited or expired awards under the existing 2019 plan. The new plan becomes effective on October 16, 2026, when the 2019 plan expires.
Stockholders also elected nine directors, including seven chosen by all voting stockholders and two elected solely by Series A preferred holders. They ratified KPMG LLP as independent auditor for 2026 and approved a non-binding advisory vote on executive compensation.
Lifecore Biomedical CEO Paul Josephs reported a tax-related share disposition. On the RSU vesting date, 40,413 shares of common stock were withheld by the company at $4.57 per share to cover withholding taxes. Josephs continues to hold 592,915 common shares directly after this transaction.
Lifecore Biomedical reports a weak quarter with revenue of $23,193 (thousands), down 34% from $35,154 (thousands), and a net loss of $14,980 (thousands). Gross margin compressed to 19.2% from 28.0% as HA manufacturing sales fell sharply and CDMO volumes declined.
Operating expenses dropped 52% to $9,134 (thousands) mainly because the prior year included a $6,851 (thousands) loss on asset sales and higher legal and professional fees. However, interest expense and the non‑cash loss from the Alcon debt derivative increased, keeping the company in a sizable loss.
Cash was $20,795 (thousands) with $17,300 (thousands) available on the revolver, while total debt principal reached $200,062 (thousands), including $188,627 (thousands) under the Alcon term loan. Redeemable preferred stock carried a $49,263 (thousands) liquidation preference and can be put to the company for cash redemption starting June 29, 2026.
Lifecore Biomedical, Inc. reported first-quarter 2026 revenue of $23.2 million, down 34% from $35.2 million in the comparable 2025 quarter, as both CDMO and hyaluronic acid manufacturing sales declined. Gross margin fell to 19% from 28%, while operating expenses dropped 52% to $9.1 million, reflecting cost containment.
The company posted a net loss of $15.0 million, or $0.43 per diluted share, similar to the prior period’s $14.8 million loss. Adjusted EBITDA was $1.0 million, down from $5.7 million. Cash from operations improved to $4.7 million and free cash flow reached $3.6 million, supported by lower capital spending.
Lifecore ended the quarter with $38.1 million of liquidity, including $20.8 million of cash and $17.3 million of revolver availability. Management reaffirmed 2026 guidance for revenue of $120–$125 million and Adjusted EBITDA of $20.5–$25 million, and highlighted three new commercial site transfer wins, ongoing margin initiatives, and the January 2026 launch of a new ERP system.
BlackRock, Inc. amended a Schedule 13G to report beneficial ownership of 1,867,916 shares of LifeCore Biomedical, Inc. common stock, representing 4.98% of the class. The filing states the stake reflects securities held by certain Reporting Business Units of BlackRock, Inc.
The cover lists CUSIP 514766104 and an address for the issuer; the amendment was signed by Spencer Fleming, Managing Director, on 04/27/2026.